HULL HANS (Chief Business Officer) sold 7.0% of their position (15.94K shares) of PLIANT THERAPEUTICS, INC. on the open market
Open‑market sale worth $178.5K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 1/22/2025ACC: 0001746473-25-000004
Officer· Chief Business Officer
Since Jun 2020
-15.94K
Net shares
Net seller
$178.5K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
15.94K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−15.94K
Price / share
$11.20
Trade value
$178.50K
% of position
7.0%
1/17/2025
227.49K→211.56K
Total
Net shares
−15.94K
Net value
-$178.50K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/17/2025 | S · Sale | −15.94K | $11.20 | $178.50K | 7.0% | 227.49K | 211.56K |
| Total | −15.94K | -$178.50K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)3
Common Stock
IndirectShares owned13.98K
Common Stock
IndirectShares owned13.98K
Common Stock
IndirectShares owned3.82K
Total
31.79K indirect31.79K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 13.98K | Indirect |
| Common Stock | 13.98K | Indirect |
| Common Stock | 3.82K | Indirect |
| Total | 31.79K | 31.79K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported